Lanreotidă Terapia (Lanreotide)

Lanreotide binds selectively to somatostatin receptors SSTR2 and SSTR5 on endocrine and tumor cells. This binding blocks adenylate cyclase, reduces cyclic AMP levels, and suppresses the secretion of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease activity.

The dosage and administration schedule for Lanreotidă Terapia are determined by the prescribing physician based on the patient’s specific condition, disease severity, and response to therapy. The prescriber will set the appropriate dose and interval.

Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lanreotide and octreotide are the two main long‑acting somatostatin analogs. Both target SSTR2 and SSTR5, but lanreotide is typically administered as a deep‑subcutaneous injection every 4–8 weeks, whereas octreotide may require more frequent dosing. Choice depends on physician preference, patient convenience, and individual response.

Lanreotidă Terapia should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional injects the prescribed volume deep into the subcutaneous tissue, usually in the abdomen or thigh, following aseptic technique. The injection schedule is set by the prescriber, often every 4 or 8 weeks.

Serious adverse events include gallstone formation, acute pancreatitis, severe hyperglycemia or new‑onset diabetes, allergic reactions such as anaphylaxis, and cardiac arrhythmias. Patients should be monitored for abdominal pain, unexplained fever, changes in blood glucose, and any signs of hypersensitivity.

Lanreotidă Terapia is contraindicated in patients with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or a history of gallbladder disease. The prescriber should evaluate each patient’s medical history before initiating therapy.